Zymeworks (ZYME) outlined its strategic priorities and key milestones for 2026. Key highlights: Positive Phase 3 HERIZON-GEA-01 results for Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma presented at ASCO GI; Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the United States, Europe, Japan, and China; Company well-positioned to execute new strategy compounding long-term value by integrating royalty growth, strategic acquisitions, and continued internal R&D innovation; $125.0 million share repurchase plan announced in November 2025 available to reduce share count
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks Sets 2026 Strategy on Zanidatamab Momentum, ADC Pipeline and Cash-Fueled Growth
- Zymeworks (ZYME): Zanidatamab’s Strong Phase 3 HERIZON-GEA Data, Global Milestones, and Royalty Model Support Buy Rating
- Zymeworks’ Ziihera Sets New Survival Benchmark in First-Line HER2-Positive Gastric Cancer Trial
- BeOne Medicines says HERIZON-GEA-01 met dual primary endpoint of PFS
- Zymeworks touts ‘unprecedented’ results from HERIZON-GEA-01 trial